The 5-year survival from lung cancer has kept pace with the improvement in 5-year survival from all cancers over the last 40 years. Yet, it remains disappointingly low at ~15%. This improvement in 5-year survival is a result of heightened awareness, better technology for detection, better selection of patients for various therapeutic options, and the selective use of palliative interventions. However, lung cancer mortality remains extraordinarily high, and it is the benchmark by which future generations will judge our success in effectively combating this disease. The Moffitt Cancer Center SPORE in Lung Cancer will 1) elucidate mechanisms of action of crucial molecules in lung carcinogenesis and tumor progression and investigate their impact on therapeutic efficacy and 2) prospectively assess the clinical utility of the molecules for therapeutic and prevention interventions. Our ultimate goal is to change the standard of care for people at risk for and with lung cancer. The SPORE has five translational research projects, three cores, a developmental research program, and a career development program. The projects are: 1) E2Fs Impact on Therapeutic Efficacy (Cress, Chen &Bepler) 2) RRM1 in the Management of Lung Cancer (Bepler, Cress &Simon) 3) Antitumor Mechanisms of Src Inhibitors in Lung Cancer (Haura, Cheng &Pledger) 4) Lung Cancer Chemoprevention with Enzastaurin (Bepler &Alexandrow) 5) p53-Based Vaccine for Small Cell Lung Cancer (Gabrilovich &Antonia) They are support by: A) Tissue Procurement, Pathology, and Bioinformatics Core (Altiok &Fenstermacher) B) Clinical Trials &Biostatistics Core (Simon, Schell &Bepler) C) Administration &Patient Advocacy Core (Bepler, Cress &Quinn). The SPORE also has Developmental Research &Career Development Programs. This SPORE will be firmly integrated into the H. Lee Moffitt Cancer Center and Research Institute, a free-standing, NCI designated Comprehensive Cancer in Tampa, Florida.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Program Officer
Ujhazy, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Pathak, Ravi Ramesh; Davé, Vrushank (2014) Integrating omics technologies to study pulmonary physiology and pathology at the systems level. Cell Physiol Biochem 33:1239-60
Remsing Rix, Lily L; Kuenzi, Brent M; Luo, Yunting et al. (2014) GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol 9:353-8
Schabath, Matthew B; Nguyen, Anthony; Wilson, Patrick et al. (2014) Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients. Lung Cancer 86:14-21
Schabath, Matthew B; McIntyre, Jessica; Pratt, Christie et al. (2014) Healthcare providers' knowledge and attitudes about rapid tissue donation (RTD): phase one of establishing a rapid tissue donation programme in thoracic oncology. J Med Ethics 40:139-42
Malaney, Prerna; Nicosia, Santo V; Dave, Vrushank (2014) One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett 344:1-12
Uversky, Vladimir N; Davé, Vrushank; Iakoucheva, Lilia M et al. (2014) Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem Rev 114:6844-79
Bai, Yun; Kim, Jae-Young; Watters, January M et al. (2014) Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. Cancer Res 74:7217-28
Donatelli, Sarah S; Zhou, Jun-Min; Gilvary, Danielle L et al. (2014) TGF-?-inducible microRNA-183 silences tumor-associated natural killer cells. Proc Natl Acad Sci U S A 111:4203-8
Gridling, Manuela; Ficarro, Scott B; Breitwieser, Florian P et al. (2014) Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics. Mol Cancer Ther 13:2751-62
Haura, Eric B; Rix, Uwe (2014) Deploying ibrutinib to lung cancer: another step in the quest towards drug repurposing. J Natl Cancer Inst 106:

Showing the most recent 10 out of 48 publications